Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis

Johanes Nugroho Eko Putranto, Johanes and Ardyan Wardhana, Ardyan and Yoga Alfian Noor, Yoga and Pirhot Lambok Marnala Yosua Siahaan, Pirhot Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis. F1000Research. ISSN 2046-1402

[img] Text (Turnitin)
01 turnitin.pdf

Download (2MB)
[img] Text (Kualitas Karil & Kesesuaian Bidang Ilmu)
01 karil.pdf

Download (393kB)
[img] Text (Artikel)
01 artikel.pdf

Download (2MB)
Official URL: https://f1000research.com/articles/10-1257

Abstract

Abstract Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation. The present meta-analysis aimed to assess the effectiveness of factor Xa inhibitors for the management of venous thromboembolism (VTE), specifically in patients with cancer, as there were more randomized clinical trials (RCTs) available. Methods: The PubMed and Cochrane Library databases were systematically screened for all RCTs assessing factor Xa inhibitor efficacy for VTE management in cancer patients. Using RevMan 5.3, we performed a Mantel-Haenszel fixed-effects meta-analysis of the following outcomes: recurrent VTE, VTE events, and major bleeding rates. Results: We identified 11 studies involving 7,965 patients. Factor Xa inhibitors were superior in preventing VTE recurrence, compared to low-molecular-weight heparin (LMWH) (OR 0.60; 95% CI 0.45-0.80; P < 0.01) and vitamin K antagonists (VKA) (OR 0.51; 95% CI 0.33-0.78; P < 0.01). As prophylaxis, factor Xa inhibitors had a similar rate of VTE compared to VKAs (OR 1.08 [95% CI 0.31-3.77]; P = 0.90) and a lower rate compared to placebo (OR 0.54 [95% CI 0.35-0.81]; P < 0.01). Major bleeding rates were higher with factor Xa inhibitors than with LMWHs (OR 1.34 [95% CI 0.83-2.18]; P = 0.23), but significantly lower than VKAs (OR 0.71 [95% CI 0.55-0.92]; P < 0.01). Conclusions: Factor Xa inhibitors are effective for VTE management in patients with cancer; however, they are also associated with an increased bleeding risk compared to LMWH, but decreased when compared to VKA.

Item Type: Article
Subjects: R Medicine > R Medicine (General) > R5-920 Medicine (General)
Creators:
CreatorsNIM
Johanes Nugroho Eko Putranto, JohanesNIDK: 8866900016
Ardyan Wardhana, ArdyanUNSPECIFIED
Yoga Alfian Noor, YogaUNSPECIFIED
Pirhot Lambok Marnala Yosua Siahaan, PirhotUNSPECIFIED
Depositing User: arys fk
Date Deposited: 25 Feb 2023 03:04
Last Modified: 25 Feb 2023 03:04
URI: http://repository.unair.ac.id/id/eprint/120120
Sosial Share:

Actions (login required)

View Item View Item